Marc Adams, MD
Radiation Oncology · Staten Island, NYNPI 1275519142
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $581 and has fallen 90.9% since, to $53 in 2025.
Across 64 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$207
- Bayer$146
- Novartis$126
- Daiichi Sankyo Inc.$98
- AstraZeneca$87
- Johnson & Johnson$79
- plus $530 from 19 others
What the payments were for
- Food & beverage$1,274100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $207 |
| Bayer | 9 | $146 |
| Novartis | 7 | $126 |
| Daiichi Sankyo Inc. | 4 | $98 |
| AstraZeneca | 5 | $87 |
| Johnson & Johnson | 3 | $79 |
| Novocure Inc. | 3 | $77 |
| Amgen | 3 | $61 |
| Incyte Corporation | 2 | $44 |
| Tactile Systems Technology Inc | 2 | $37 |
| Blueprint Medicines Corporation | 1 | $36 |
| Genmab U.S., Inc. | 1 | $32 |
| Beigene USA, Inc. | 1 | $31 |
| Boston Scientific | 2 | $29 |
| Lilly USA, LLC | 1 | $21 |
| G1 Therapeutics, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| AbbVie | 1 | $15 |
| Qfix | 1 | $14 |
| Angiodynamics, Inc. | 1 | $13 |
| Blue Earth Diagnostics | 1 | $12 |
How this compares
$1,274 in reported general payments places this provider in the 70th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 16 | $150 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Staten Island
- Chung ChungSyracuse$3.1M
- Michael ZelefskyNew York$946K
- Jeffrey BogartSyracuse$772K
- Steven FinkelsteinSyracuse$578K
- Shawn ZimbergPlainview$411K
- Edward ObedianOyster Bay$391K
- Nancy LeeNew York$233K
- Dheerendra PrasadBuffalo$178K
- Robert SamsteinNew York$125K
- Jalal AhmedNew York$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.